Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization

被引:216
作者
Angeli, V
Llodrá, J
Rong, JX
Satoh, K
Ishii, S
Shimizu, T
Fisher, EA
Randolph, GJ [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA
[2] NYU, Marc & Ruti Bell Vasc Biol & Dis Program, New York, NY 10016 USA
[3] NYU, New York Univ Lipid Treatment & Res Ctr, New York, NY 10016 USA
[4] Hirosaki Univ, Sch Med, Dept Vasc Biol, Hirosaki, Aomori 0368562, Japan
[5] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 1130033, Japan
关键词
D O I
10.1016/j.immuni.2004.09.003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
High LDL and/or low HDL are risk factors for atherosclerosis and are also a common clinical feature in systemic lupus erythematosus, rheumatoid arthritis, and psoriasis. Here, we show that changes in lipid profiles that reflect atherosclerotic disease led to activation of skin murine dendritic cells (DCs) locally, promoted dermal inflammation, and induced lymph node hypertrophy. Paradoxically, DC migration to lymph nodes was impaired, suppressing immunologic priming. Impaired migration resulted from inhibitory signals generated by platelet-activating factor (PAF) or oxidized LDL that acts as a PAF mimetic. Normal DC migration and priming was restored by HDL or HDL associated PAF acetylhydrolase (PAFAH), which mediates inactivation of PAF and oxidized LDL. Thus, atherosclerotic changes can sequester activated DCs in the periphery where they may aggravate local inflammation even as they poorly carry out functions that require their migration to lymph nodes. In this context, HDL and PAFAH maintain a normally functional DC compartment.
引用
收藏
页码:561 / 574
页数:14
相关论文
共 71 条
[21]   Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome [J].
Hayem, G ;
Nicaise-Roland, P ;
Palazzo, E ;
de Bandt, M ;
Tubach, F ;
Weber, M ;
Meyer, O .
LUPUS, 2001, 10 (05) :346-351
[22]   OXIDATIVELY MODIFIED LDL CONTAINS PHOSPHOLIPIDS WITH PLATELET-ACTIVATING FACTOR-LIKE ACTIVITY AND STIMULATES THE GROWTH OF SMOOTH-MUSCLE CELLS [J].
HEERY, JM ;
KOZAK, M ;
STAFFORINI, DM ;
JONES, DA ;
ZIMMERMAN, GA ;
MCINTYRE, TM ;
PRESCOTT, SM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2322-2330
[23]  
IIOWITE NT, 1988, ARTHRITIS RHEUM, V31, P859
[24]   Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice [J].
Ishii, S ;
Shimizu, T .
PROGRESS IN LIPID RESEARCH, 2000, 39 (01) :41-82
[25]   Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor [J].
Ishii, S ;
Kuwaki, T ;
Nagase, T ;
Maki, K ;
Tashiro, F ;
Sunaga, S ;
Cao, WH ;
Kume, K ;
Fukuchi, Y ;
Ikuta, K ;
Miyazaki, J ;
Kumada, M ;
Shimizu, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1779-1788
[26]   Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity [J].
Itano, AA ;
McSorley, SJ ;
Reinhardt, RL ;
Ehst, BD ;
Ingulli, E ;
Rudensky, AY ;
Jenkins, MK .
IMMUNITY, 2003, 19 (01) :47-57
[27]  
Laskowitz DT, 2000, J LIPID RES, V41, P613
[28]  
Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]
[29]   Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques [J].
Llodrá, J ;
Angeli, V ;
Liu, JH ;
Trogan, E ;
Fisher, EA ;
Randolph, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (32) :11779-11784
[30]   Immunopathogenesis of atherosclerosis [J].
Ludewig, B ;
Krebs, P ;
Scandella, E .
JOURNAL OF LEUKOCYTE BIOLOGY, 2004, 76 (02) :300-306